Alto Neuroscience Inc is a pioneering biopharmaceutical company focused on developing innovative treatments for mental health conditions such as major depressive disorder (MDD), post-traumatic stress disorder, cognitive impairments associated with schizophrenia, and more. With a robust pipeline including ALTO-100, ALTO-300, ALTO-101, ALTO-203, and ALTO-202, Alto Neuroscience leverages cutting-edge science and an AI-enabled biomarker platform to tailor therapies to individual patient needs. Founded in 2019 and based in Los Altos, California, the company is at the forefront of addressing unmet needs in psychiatric medicine.
Are you looking for low-cost stocks to add to your portfolio? Doing so can be a challenge. After all, stocks that trade with low share prices are often risky investment opportunities. That’s…
